Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET

Company Participants

Francesca Nolan - IR Director

Douglas Ingram - President and CEO

Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development

Dallan Murray - EVP & Chief Customer Officer

Ian Estepan - EVP & CFO

Conference Call Participants

Anupam Rama - JPMorgan

Tazeen Ahmad - Bank of America Securities

Gena Wang - Barclays

Colin Bristow - UBS

Brian Skorney - Baird

Salveen Richter - Goldman Sachs

Uy Ear - Mizuho

Danielle Brill - Raymond James

Ritu Baral - TD Cowen

Mike Ulz - Morgan Stanley

Tim Lugo - William Blair

Gil Blum - Needham & Company

Brian Abrahams - RBC Capital

Jason Bouvier - Cantor Fitzgerald

Joseph Schwartz - Leerink Partners

Operator

Good afternoon and welcome to the Sarepta Therapeutics Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

At this time. I'll turn the call over to Francesca Nolan, Executive Director, Investor Relations and Corporate Communications. Please go ahead.

Francesca Nolan

Thank you, Jonathan. And thank you all for joining today's call. Earlier this afternoon, we released our financial results for the third quarter 2023. The press release is available on our website at sarepta.com and our 10-Q was filed with the Securities and Exchange Commission this afternoon.

Joining us on the call today, are Doug Ingram; Ian Estepan; Dallan Murray and Dr. Louise Rodino-Klapac. After our further remarks, we'll open the call for Q&A.

I'd like to know that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slides on the webcast which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements and any such risks can materially adversely affect the business, the results of operations and trading prices for Sarepta's common stock.

For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent quarterly report on Form 10-Q filed with the SEC, as well as the company's other SEC filings. The Company does not undertake any obligation to publicly update its forward-looking statement, including any financial projections provided today based on subsequent events or circumstances.